How to accelerate bringing new drugs to patients: role of clinical trials networks Source: International Congress 2019 – Rare lung diseases Year: 2019
Evidence provided by recent meta-analyses on treatment: what is new? Source: Annual Congress 2012 - PG7 TB and MDR-/XDR-TB: what is new in diagnosis, treatment and follow-up (TB PAN-NET) Year: 2012
Key role of patients in clinical trials Source: Research Seminar 2013 - ERS Presidential Summit on Research gaps, patient needs and innovative solutions: a forward look on lung health research Year: 2013
Noninvasive strategies in COVID-19: epistemology, randomised trials, guidelines, physiology Source: Eur Respir J, 57 (2) 2004247; 10.1183/13993003.04247-2020 Year: 2021
New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response Source: Eur Respir Rev 2014; 23: 367-378 Year: 2014
Clinical use of new and repurposed drugs: the role and contribution of the ERS collaborative projects Source: International Congress 2017 – In the frontline of the fight against tuberculosis Year: 2017
Clinical trial landscape for M/XDR-TB: current evidence and future perspectives Source: International Congress 2019 – Recent developments and future perspectives in the diagnosis and treatment of tuberculosis Year: 2019
SARS-CoV-2 disrupts clinical research: the role of a rare disease-specific trial network Source: Eur Respir J, 56 (3) 2002114; 10.1183/13993003.02114-2020 Year: 2020
The future of translational lung cancer research: from classical randomised controlled trials to innovative platform trials Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer Year: 2018
COPD and new treatment options: the role of primary care Source: International Congress 2014 – Primary Care Programme "Management of COPD and other respiratory conditions in clinical practice" Year: 2014
Efficacy of acupuncture in asthma: systematic review and meta-analysis of published data from 11 randomised controlled trials Source: Eur Respir J 2002; 20: 846-852 Year: 2002
Do the current endpoints in IPF clinical trials allow good regulatory decisions to be made? Source: International Congress 2014 – Ceremony for the ERS Rare Pulmonary Disease Research Award 2014 followed by the symposium "Challenges in endpoints for rare lung diseases" Year: 2014
Negative clinical trials in sarcoidosis: failed therapies or flawed study design? Source: Eur Respir J 2014; 44: 1123-1126 Year: 2014
Efficacy and safety of new drugs for M/XDR-TB: what have we learned from observational studies? Source: International Congress 2019 – Recent developments and future perspectives in the diagnosis and treatment of tuberculosis Year: 2019
Evidence of efficacy for sequential combination therapy in recent randomized controlled trials (RCTs) Source: International Congress 2014 – Combination therapy in pulmonary arterial hypertension (PAH): the evidence grows Year: 2014
Clinical effectiveness of triple therapy in the management of COPD: A systematic review Source: Annual Congress 2010 - Risk factors, prevalence and consequences of COPD Year: 2010